Ascendis Pharma A/S
ASND US
ASND USAscendis Pharma A/S
United States Composite141.01
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
- Business
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Company News
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Biotech With 520% Sales Growth Nears Next Buy Point
Two Health Care Stocks Outperform S&P 500, Offer Entries
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
Buy Rating Affirmed for Ascendis Pharma Amid Favorable Market Dynamics and Strong TransCon PTH Outlook
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?